Experience with early use of certolizumab pegol in able-bodied patients with axial spondyloarthritis in the framework of a model for clinical statistical groups
Axial spondyloarthritis (axSpA) is an immune-mediated inflammatory disease that affects predominantly the sacroiliac joints and spine. The main goal of axSpA therapy is to slow down and prevent structural damages that become a main cause of disability in able-bodied patients. Timely diagnosis and ea...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2020-09-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1056 |